VEGFR Inhibitor-Resistant Thyroid Cancer Responds to Cabozantinib [Clinical Trials]

Cabozantinib achieved partial responses in 40% of patients with differentiated thyroid cancer (DTC).

from Cancer via ola Kala on Inoreader http://ift.tt/2wvfXmI
via IFTTT